BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25667480)

  • 21. Comparison of dual-time point 18F-FDG PET/CT tumor-to-background ratio, intraoperative 5-aminolevulinic acid fluorescence scale, and Ki-67 index in high-grade glioma.
    Kim YI; Cho KG; Jang SJ
    Medicine (Baltimore); 2019 Feb; 98(8):e14397. PubMed ID: 30813140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
    Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
    Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
    Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
    J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of 18F-FDG PET at conventional and delayed intervals for the discrimination of high-grade from low-grade gliomas: a stereotactic PET and MRI study.
    Mertens K; Acou M; Van Hauwe J; De Ruyck I; Van den Broecke C; Kalala JP; D'Asseler Y; Goethals I
    Clin Nucl Med; 2013 Jul; 38(7):495-500. PubMed ID: 23640217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
    Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
    J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
    Koolen BB; Elshof LE; Loo CE; Wesseling J; Vrancken Peeters MJ; Vogel WV; Rutgers EJ; Valdés Olmos RA
    Eur J Radiol; 2013 Dec; 82(12):2353-8. PubMed ID: 23998705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography.
    Ferda J; Ferdová E; Baxa J; Kreuzberg B; Daum O; Třeška V; Skalický T
    Anticancer Res; 2015 Apr; 35(4):2241-6. PubMed ID: 25862885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.
    Fushiki H; Miyoshi S; Noda A; Murakami Y; Sasaki H; Jitsuoka M; Mitsuoka K; Matsunari I; Nishimura S
    Anticancer Res; 2013 Nov; 33(11):4741-9. PubMed ID: 24222108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of quantitative criteria for glioma grading with static and dynamic 18F-FDopa PET/CT.
    Nioche C; Soret M; Gontier E; Lahutte M; Dutertre G; Dulou R; Capelle L; Guillevin R; Foehrenbach H; Buvat I
    Clin Nucl Med; 2013 Feb; 38(2):81-7. PubMed ID: 23334119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
    J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.
    Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A
    Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
    Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.